Patients with rare bone cancer still have low survival rates
the ONA take:
Mesenchymal chondrosarcoma remains classified among the more deadly cancer types, but a recent study has indicated that survival for this disease may not be as low as was previously thought.
A Loyola University Medical Center study, led by senior author Lukas Nystrom, MD, reviewed survival for 205 individuals with mesenchymal chondrosarcoma (cases occurring between 1973 and 2011).
Data was sourced from the Surveillance, Epidemiology and End Results (SEER) program database, which is administered through the National Cancer Institute (NCI). Fifty-one percent survived a minimum of 5 years, and 43 percent survived 10 years or more. survival rates observed differed, depending on the tumor location: an axial location demonstrated a lower survival rate.
Dr. Nystrom has suggested that this lower survival outcome could be attributable to the inoperable location of the axial tumors.
Improved screening techniques and technology could be a factor in the lowering (if still high) mortality rates overall.
Mesenchymal chondrosarcoma remains classified among the more deadly cancer types.
- Sexual Dysfunction in Women With Cancer: A Review of Available Interventions
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
- Geriatric Consults Rare in Kidney Cancer Care
- Worse Survival Seen for Alternative Versus Usual Cancer Therapy
- Anorexia-Cachexia in Non-Small Cell Lung Cancer Improved With Anamorelin
- Early Recognition of Checkpoint Inhibitor-Related Pneumonitis Improves Outcomes
- Lenalidomide After ASCT Prolongs Time to Progression in Multiple Myeloma
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|